2000
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer
Farrow D, Vaughan T, Sweeney C, Gammon M, Chow W, Risch H, Stanford J, Hansten P, Mayne S, Schoenberg J, Rotterdam H, Ahsan H, West A, Dubrow R, Fraumeni J, Blot W. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes & Control 2000, 11: 231-238. PMID: 10782657, DOI: 10.1023/a:1008913828105.Peer-Reviewed Original ResearchConceptsGastroesophageal reflux diseaseNon-cardia gastric adenocarcinomaEsophageal adenocarcinomaGERD symptomsReflux diseaseH2 blockersGastric adenocarcinomaGastric cancerLarge population-based case-control studyPopulation-based case-control studyPopulation-based tumor registryEsophageal squamous cell carcinomaPerson structured interviewRisk of esophagealSquamous cell carcinomaEsophageal adenocarcinoma riskH2-receptor antagonistsCase-control studyGastric cardia adenocarcinomaRandom digit dialingLong-term usersTumor RegistryAdenocarcinoma riskDaily symptomsCell carcinoma
1995
The accuracy of prostate cancer staging in a population-based tumor registry and its impact on the Black-White stage difference (Connecticut, United States)
Liu W, Kasl S, Flannery J, Lindo A, Dubrow R. The accuracy of prostate cancer staging in a population-based tumor registry and its impact on the Black-White stage difference (Connecticut, United States). Cancer Causes & Control 1995, 6: 425-430. PMID: 8547540, DOI: 10.1007/bf00052182.Peer-Reviewed Original ResearchConceptsConnecticut Tumor RegistryProstate cancerTumor RegistryMedical recordsPopulation-based tumor registryIncomplete medical recordsDistant stage diseaseProstate cancer stageDifferent cancer sitesPercent of blacksStage diseaseAccurate stagingPercent of whitesCancer stageCancer sitesRoutine codingStudy membersCancerWhite menRegistryStage differencesDiseaseManagement errorsDiagnosisMajor determinant